ストックスクリーナーアプリを入手
6.79
3.82%
0.25
アフターアワーズ：
6.78
-0.010
-0.15%
Annovis Bio Inc (ANVS) 最新ニュース
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MSN
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MSN
When the Price of (ANVS) Talks, People Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s - Barchart
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright - MarketBeat
Annovis Bio (NYSE: ANVS) CEO To Showcase Buntanetap’s Dual Benefits At NIA Workshop - Barchart
Veravas and Phanes Biotech Collaborate to Innovate Alzheimer’s Disease Testing - MyChesCo
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - GlobeNewswire
Annovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial Backing - Barchart
Annovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Annovis sees cash runway for Phase 3 preparatory studies, entering AD study - Nasdaq
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Yahoo Finance
Annovis Bio Inc (ANVS) Quarterly 10-Q Report - Quartzy
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist - citybiz
Annovis Bio (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease Conference - Barchart
(ANVS) Technical Pivots with Risk Controls - Stock Traders Daily
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - GlobeNewswire
Annovis Bio (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients - Barchart
Brokerages Set Annovis Bio, Inc. (NYSE:ANVS) PT at $32.17 - MarketBeat
Annovis Bio (NYSE:ANVS) Raised to Buy at Maxim Group - MarketBeat
Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference - MSN
Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies - Barchart
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 - The Manila Times
Annovis Bio files three drug patents - Pennsylvania Business Report
Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio To Continue Alzheimer's Disease Clinical Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug - Yahoo Finance
Annovis Bio shares hold Buy rating from HC Wainwright - Investing.com India
Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish - Barchart
Annovis Bio shares hold Buy rating from HC Wainwright By Investing.com - Investing.com UK
In the Green: Annovis Bio Inc (ANVS) Closes at 7.98, Up/Down 6.26 from Previous Day - The Dwinnex
Annovis Bio (NYSE:ANVS) Given Buy Rating at HC Wainwright - MarketBeat
(ANVS) Investment Analysis and Advice - Stock Traders Daily
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials - MyChesCo
Annovis Bio (ANVS) Stock Soars After FDA Approval - Stocks Telegraph
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - The Manila Times
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs - GlobeNewswire
Freedom Village Hosts Successful Third Annual Walk to End Alzheimer’s - MyChesCo
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):